Maria Luisa Esposito

TL;DR: It is demonstrated that vaccines developed with adenoviral vectors can induce broad and sustained immune responses to HCV in humans and open the way for studies of prophylactic and therapeutic vaccines for HCV.

TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.

TL;DR: It is shown that rare serotypes of human adenoviruses, which should not be neutralized in most humans, are far less potent as vaccine vectors than Ad5 in mice and nonhuman primates, casting doubt on their potential efficacy in humans.

TL;DR: Vaccination with potent HCV adenoviral vectored vaccines fails to restore T‐ cell immunity except where there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the major challenge of overcoming T‐cell exhaustion in the context of persistent antigen exposure with implications for cancer and other persistent infections.

TL;DR: It is shown that the vectored RSV vaccine induces potent cellular and humoral responses in a primate model, providing strong support for clinical testing, and generating a new genetic vaccine based on chimpanzee Adenovirus and Modified Vaccinia Ankara RSV, for the induction of neutralizing antibodies and broad cellular immunity.